Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure mounts on US FDA to address alleged persistent sexual dysfunction with Merck's hair loss drug

This article was originally published in Scrip

Executive Summary

As physicians call for the US FDA to address reports of persistent sexual dysfunction with Merck & Co's male-pattern hair loss drug Propecia (finasteride), the US Judicial Panel on Multidistrict Litigation in San Diego, California, has scheduled a 29 March hearing session that will determine if a number of individual law suits filed against the company should be "centralised" in one legal action.

You may also be interested in...



Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone

Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).

AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib

AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.

Solid but not spectacular: Victoza's weight loss verdict in non-diabetics

Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016564

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel